Anti-Hypertensive Drugs - Peru

Peru

The Anti-Hypertensive Drugs market in Peru is predicted to achieve a revenue of US$23.64m in 2024.
It is expected to exhibit a Compound Annual Growth Rate (CAGR) of -0.12% from 2024 to 2029, leading to a market volume of US$23.50m by 2029.
When compared globally, United States is projected to generate the highest revenue, amounting to US$12,290.00m in 2024.
Peru's anti-hypertensive drug market is experiencing a surge in demand as the country grapples with a high prevalence of hypertension among its population.

Key regions: Japan, India, Italy, Brazil, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for anti-hypertensive drugs in Peru has been on the rise in recent years.

Customer preferences: Peruvian consumers have shown a growing awareness of the importance of managing their blood pressure and taking preventative measures against hypertension. As a result, the demand for anti-hypertensive drugs has increased steadily. Additionally, the aging population in Peru has contributed to the growth of this market segment.

Trends in the market: One of the key trends in the anti-hypertensive drug market in Peru is the increasing availability of generic drugs. The government has implemented policies to promote the use of generic drugs, which has led to a decrease in prices and increased access for consumers. Another trend is the shift towards combination therapies, which offer more effective treatment options for patients.

Local special circumstances: Peru has a diverse population with varying healthcare needs depending on their location and socioeconomic status. This has led to disparities in access to healthcare and medication. Additionally, there is a lack of awareness and education on hypertension in some communities, which can lead to underdiagnosis and undertreatment.

Underlying macroeconomic factors: Peru has experienced steady economic growth in recent years, which has led to an increase in healthcare spending. Additionally, the government has implemented policies to increase access to healthcare and medication for all citizens. However, there are still challenges in terms of infrastructure and resources, particularly in rural areas.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.